Skip to main content

Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).

Publication ,  Conference
Khasraw, M; McCowatt, SA; Kerestes, Z; Buyse, ME; Back, M; Wheeler, H
Published in: Journal of Clinical Oncology
May 20, 2011

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2011

Volume

29

Issue

15_suppl

Start / End Page

TPS133 / TPS133

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khasraw, M., McCowatt, S. A., Kerestes, Z., Buyse, M. E., Back, M., & Wheeler, H. (2011). Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric). In Journal of Clinical Oncology (Vol. 29, pp. TPS133–TPS133). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2011.29.15_suppl.tps133
Khasraw, M., S. A. McCowatt, Z. Kerestes, M. E. Buyse, M. Back, and H. Wheeler. “Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).” In Journal of Clinical Oncology, 29:TPS133–TPS133. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.tps133.
Khasraw M, McCowatt SA, Kerestes Z, Buyse ME, Back M, Wheeler H. Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011. p. TPS133–TPS133.
Khasraw, M., et al. “Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2011, pp. TPS133–TPS133. Crossref, doi:10.1200/jco.2011.29.15_suppl.tps133.
Khasraw M, McCowatt SA, Kerestes Z, Buyse ME, Back M, Wheeler H. Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011. p. TPS133–TPS133.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2011

Volume

29

Issue

15_suppl

Start / End Page

TPS133 / TPS133

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences